Clinical and biological characteristics of patients with AML
| Variable . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 26 (52) |
| Female | 24 (48) |
| Age at diagnosis, y (%) | |
| <50 | 15 (30) |
| ≥50 | 35 (70) |
| Median, y | 56 |
| Range, y | 21-69 |
| Peripheral blood white cell count | |
| <30 000/mm3, n (%) | 29 (58) |
| ≥30 000/mm3, n (%) | 21 (42) |
| Median (109 cells/L) | 23.6 |
| Range (109 cells/L) | 0.4-385 |
| Circulating blasts, % | |
| Median | 32 |
| Range | 0-99 |
| Bone marrow blasts, % | |
| Median | 60 |
| Range | 23-96 |
| Diagnosis, n (%) | |
| De novo AML | 41 (82) |
| Secondary AML (MDS-related) | 7 (14) |
| Secondary AML (therapy-related) | 2 (4) |
| FAB classification, n (%) | |
| M0 | 1 (2) |
| M1 | 14 (28) |
| M2 | 15 (30) |
| M4 | 11 (22) |
| M5 | 5 (10) |
| M6 | 2 (4) |
| MDS RAEB-T | 2 (4) |
| Cytogenetic profile,* n (%) | |
| Favorable | 4 (8) |
| Intermediate | 34 (68) |
| Unfavorable | 8 (16) |
| Missing data | 4 (8) |
| Molecular features, n (%) | |
| NPM1 mutation | 19 (38) |
| FLT3/ITD translocation | 14 (28) |
| MLL mutation | 4 (8) |
| RUNX1/RUNX1T1 translocation | 3 (6) |
| CEBPA mutation | 2 (4) |
| CBFB/MYH11 translocation | 1 (2) |
| Induction chemotherapy, n (%) | |
| Daunorubicine 90 mg/m2 3 d + Cytarabine 100 mg/m2 7 d | 35 (70) |
| Idarubicine 10 mg/m2 3 d + Cytarabine 100 mg/m2 7 d | 14 (28) |
| Fludarabine 15 mg/m2 + Cytarabine 500 mg/m2 twice-daily 4 d | 1 (2) |
| Consolidation therapy, n (%) | |
| Chemotherapy only | 34 (68) |
| Hematopoietic stem cell transplantation | 28 (56) |
| Treatment response, n (%) | |
| Complete remission | 38 (76) |
| After 1 induction cycle | 29 (58) |
| After 2 induction cycles | 9 (18) |
| Induction failure | 11 (22) |
| Death in aplasia | 1 (2) |
| Variable . | Value . |
|---|---|
| Sex, n (%) | |
| Male | 26 (52) |
| Female | 24 (48) |
| Age at diagnosis, y (%) | |
| <50 | 15 (30) |
| ≥50 | 35 (70) |
| Median, y | 56 |
| Range, y | 21-69 |
| Peripheral blood white cell count | |
| <30 000/mm3, n (%) | 29 (58) |
| ≥30 000/mm3, n (%) | 21 (42) |
| Median (109 cells/L) | 23.6 |
| Range (109 cells/L) | 0.4-385 |
| Circulating blasts, % | |
| Median | 32 |
| Range | 0-99 |
| Bone marrow blasts, % | |
| Median | 60 |
| Range | 23-96 |
| Diagnosis, n (%) | |
| De novo AML | 41 (82) |
| Secondary AML (MDS-related) | 7 (14) |
| Secondary AML (therapy-related) | 2 (4) |
| FAB classification, n (%) | |
| M0 | 1 (2) |
| M1 | 14 (28) |
| M2 | 15 (30) |
| M4 | 11 (22) |
| M5 | 5 (10) |
| M6 | 2 (4) |
| MDS RAEB-T | 2 (4) |
| Cytogenetic profile,* n (%) | |
| Favorable | 4 (8) |
| Intermediate | 34 (68) |
| Unfavorable | 8 (16) |
| Missing data | 4 (8) |
| Molecular features, n (%) | |
| NPM1 mutation | 19 (38) |
| FLT3/ITD translocation | 14 (28) |
| MLL mutation | 4 (8) |
| RUNX1/RUNX1T1 translocation | 3 (6) |
| CEBPA mutation | 2 (4) |
| CBFB/MYH11 translocation | 1 (2) |
| Induction chemotherapy, n (%) | |
| Daunorubicine 90 mg/m2 3 d + Cytarabine 100 mg/m2 7 d | 35 (70) |
| Idarubicine 10 mg/m2 3 d + Cytarabine 100 mg/m2 7 d | 14 (28) |
| Fludarabine 15 mg/m2 + Cytarabine 500 mg/m2 twice-daily 4 d | 1 (2) |
| Consolidation therapy, n (%) | |
| Chemotherapy only | 34 (68) |
| Hematopoietic stem cell transplantation | 28 (56) |
| Treatment response, n (%) | |
| Complete remission | 38 (76) |
| After 1 induction cycle | 29 (58) |
| After 2 induction cycles | 9 (18) |
| Induction failure | 11 (22) |
| Death in aplasia | 1 (2) |
CBFB, core binding factor β; CEBPA, CCAAT/enhancer-binding protein alfa; FAB, Franco-Americano-British; FLT3, Fms-like tyrosine kinase 3; ITD, internal tandem duplication; MLL, mixed-lineage leukemia; MDS, myelodysplastic syndrome; MYH11, myosin heavy chain 11; NPM1, nucleophosmin 1; RAEB-T, refractory anemia with excess blasts in transformation; RUNX1, runt-related transcription factor 1; RUNX1T1, RUNX1 translocation partner 1.
Per Grimwade et al.40